A detailed history of Marshall Wace, LLP transactions in Lexicon Pharmaceuticals, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 574,150 shares of LXRX stock, worth $476,544. This represents 0.0% of its overall portfolio holdings.

Number of Shares
574,150
Previous 1,190,448 51.77%
Holding current value
$476,544
Previous $2 Million 54.93%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.51 - $2.39 $930,609 - $1.47 Million
-616,298 Reduced 51.77%
574,150 $901,000
Q2 2024

Aug 14, 2024

BUY
$1.54 - $2.28 $1.06 Million - $1.58 Million
691,276 Added 138.48%
1,190,448 $2 Million
Q1 2024

May 15, 2024

BUY
$1.3 - $3.58 $648,923 - $1.79 Million
499,172 New
499,172 $1.2 Million
Q2 2023

Aug 14, 2023

BUY
$2.15 - $3.49 $269,367 - $437,251
125,287 New
125,287 $286,000
Q4 2020

Feb 16, 2021

SELL
$1.05 - $3.67 $295,729 - $1.03 Million
-281,647 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$1.44 - $2.1 $943,119 - $1.38 Million
-654,944 Reduced 69.93%
281,647 $406,000
Q2 2020

Aug 13, 2020

SELL
$1.75 - $2.3 $715,783 - $940,743
-409,019 Reduced 30.4%
936,591 $1.87 Million
Q1 2020

May 15, 2020

BUY
$1.8 - $4.28 $890,427 - $2.12 Million
494,682 Added 58.13%
1,345,610 $2.62 Million
Q4 2019

Feb 14, 2020

BUY
$3.16 - $5.15 $2.69 Million - $4.38 Million
850,928 New
850,928 $3.53 Million
Q1 2019

May 14, 2019

SELL
$4.36 - $7.94 $1.15 Million - $2.1 Million
-264,139 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$6.15 - $10.51 $1.41 Million - $2.42 Million
229,876 Added 670.92%
264,139 $1.75 Million
Q3 2018

Nov 14, 2018

SELL
$10.32 - $13.06 $6.36 Million - $8.05 Million
-616,555 Reduced 94.74%
34,263 $366,000
Q2 2018

Aug 14, 2018

SELL
$7.8 - $13.69 $668,670 - $1.17 Million
-85,727 Reduced 11.64%
650,818 $7.81 Million
Q1 2018

May 15, 2018

BUY
$7.86 - $11.39 $5.79 Million - $8.39 Million
736,545 New
736,545 $6.31 Million

Others Institutions Holding LXRX

About LEXICON PHARMACEUTICALS, INC.


  • Ticker LXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 188,726,000
  • Market Cap $157M
  • Description
  • Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...
More about LXRX
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.